Publication:
Inflammatory markers are associated with the progression of gestational diabetes to metabolic syndrome

dc.contributor.coauthorCan, Bulent
dc.contributor.coauthorCan, Busra
dc.contributor.coauthorKeskin, Havva
dc.contributor.coauthorBekpinar, Seldag
dc.contributor.coauthorDinccag, Nevin
dc.contributor.departmentN/A
dc.contributor.kuauthorTütüncü, Yıldız
dc.contributor.kuprofileFaculty Member
dc.contributor.schoolcollegeinstituteSchool of Medicine
dc.contributor.yokid239430
dc.date.accessioned2024-11-09T23:25:14Z
dc.date.issued2022
dc.description.abstractThe progression of gestational diabetes mellitus (GDM) to metabolic syndrome (MetS) is associated with systemic inflammation. The aim of this study was to compare the levels of inflammatory markers in former GDM patients with and without MetS. Medical records were screened retrospectively for patients who were diagnosed with GDM 10 (±2) years ago. Former GDM patients were invited to the hospital for an assessment of their current health status. Of 52 women with former GDM, 27 (52%) had MetS. C-reactive protein (CRP), interleukin-6 and plasminogen activator inhibitor-1 (PAI-1) levels were significantly higher in the MetS group while adiponectin was significantly lower (p < .001, p = .037, p = .002 and p = .013, respectively). There was no significant difference in plasma levels of visfatin and tumour necrosis factor-α. Interleukin-6, CRP, PAI-1 and adiponectin may be used as biomarkers to detect MetS in the pre-clinical phase. With timely diagnosis, early interventions can be implemented.
dc.description.indexedbyWoS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.issue6
dc.description.openaccessNO
dc.description.publisherscopeInternational
dc.description.sponsorshipIstanbul University Scientific Research Projects Coordination Unit [12-24457] This work was supported by the Istanbul University Scientific Research Projects Coordination Unit [grant number 12-24457].
dc.description.volume42
dc.identifier.doi10.1080/01443615.2022.2048363
dc.identifier.eissn1364-6893
dc.identifier.issn0144-3615
dc.identifier.quartileQ4
dc.identifier.scopus2-s2.0-85130009608
dc.identifier.urihttp://dx.doi.org/10.1080/01443615.2022.2048363
dc.identifier.urihttps://hdl.handle.net/20.500.14288/11345
dc.identifier.wos787235800001
dc.keywordsInterleukin-6
dc.keywordsPai-1
dc.keywordsAdiponectin
dc.keywordsGestational diabetes
dc.keywordsMetabolic syndrome insulin-resistance
dc.keywordsAdiponectin levels
dc.keywordsVisfatin
dc.keywordsObesity
dc.keywordsDiagnosis
dc.keywordsMellitus
dc.keywordsWomen
dc.keywordsRisk
dc.languageEnglish
dc.publisherTaylor and Francis Inc
dc.sourceJournal of Obstetrics and Gynaecology
dc.subjectObstetrics
dc.subjectGynecology
dc.titleInflammatory markers are associated with the progression of gestational diabetes to metabolic syndrome
dc.typeJournal Article
dspace.entity.typePublication
local.contributor.authorid0000-0002-3905-6429
local.contributor.kuauthorTütüncü, Yıldız

Files